News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
268,201 Results
Type
Article (14263)
Company Profile (281)
Press Release (253657)
Multimedia
Podcasts (48)
Webinars (7)
Section
Business (79531)
Career Advice (153)
Deals (13230)
Drug Delivery (35)
Drug Development (50466)
Employer Resources (31)
FDA (5727)
Job Trends (5135)
News (144443)
Policy (10033)
Tag
Academia (917)
Accelerated approval (2)
Adcomms (12)
Allergies (52)
Alliances (21673)
ALS (64)
Alzheimer's disease (849)
Antibody-drug conjugate (ADC) (100)
Approvals (5754)
Artificial intelligence (124)
Autoimmune disease (18)
Automation (5)
Bankruptcy (105)
Best Places to Work (4561)
BIOSECURE Act (6)
Biosimilars (43)
Biotechnology (232)
Bladder cancer (59)
Brain cancer (20)
Breast cancer (155)
Cancer (1485)
Cardiovascular disease (117)
Career advice (134)
Career pathing (2)
CAR-T (118)
Cell therapy (332)
Cervical cancer (8)
Clinical research (41097)
Collaboration (542)
Compensation (263)
Complete response letters (13)
COVID-19 (1034)
CRISPR (42)
C-suite (165)
Cystic fibrosis (76)
Data (1531)
Denatured (11)
Depression (31)
Diabetes (139)
Diagnostics (1300)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (85)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (90)
Earnings (29858)
Editorial (18)
Employer branding (4)
Employer resources (29)
Events (48627)
Executive appointments (464)
FDA (6434)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (498)
Gene editing (97)
Generative AI (10)
Gene therapy (254)
GLP-1 (371)
Government (1082)
Grass and pollen (2)
Guidances (27)
Healthcare (6595)
Huntington's disease (22)
IgA nephropathy (25)
Immunology and inflammation (92)
Indications (20)
Infectious disease (1099)
Inflammatory bowel disease (115)
Inflation Reduction Act (8)
Influenza (19)
Intellectual property (67)
Interviews (17)
IPO (7274)
IRA (11)
Job creations (861)
Job search strategy (128)
Kidney cancer (7)
Labor market (5)
Layoffs (210)
Leadership (3)
Legal (1386)
Liver cancer (33)
Lung cancer (205)
Lymphoma (102)
Machine learning (3)
Management (7)
Manufacturing (140)
MASH (54)
Medical device (2600)
Medtech (2601)
Mergers & acquisitions (6287)
Metabolic disorders (391)
Multiple sclerosis (53)
NASH (13)
Neurodegenerative disease (69)
Neuropsychiatric disorders (25)
Neuroscience (1262)
NextGen: Class of 2025 (2017)
Non-profit (853)
Now hiring (21)
Obesity (194)
Opinion (102)
Ovarian cancer (63)
Pain (44)
Pancreatic cancer (56)
Parkinson's disease (122)
Partnered (8)
Patents (130)
Patient recruitment (79)
Peanut (35)
People (25654)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14518)
Phase II (19113)
Phase III (12086)
Pipeline (818)
Policy (46)
Postmarket research (852)
Preclinical (6141)
Press Release (30)
Prostate cancer (62)
Psychedelics (35)
Radiopharmaceuticals (213)
Rare diseases (292)
Real estate (1419)
Recruiting (12)
Regulatory (8649)
Reports (15)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (4)
RNA editing (5)
RSV (10)
Schizophrenia (61)
Series A (98)
Series B (63)
Service/supplier (1)
Sickle cell disease (40)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (12)
Startups (1975)
State (1)
Stomach cancer (4)
Supply chain (23)
Tariffs (9)
The Weekly (36)
Vaccines (214)
Venture capitalists (32)
Weight loss (110)
Women's health (15)
Worklife (2)
Date
Today (81)
Last 7 days (542)
Last 30 days (1499)
Last 365 days (19527)
2025 (6353)
2024 (20552)
2023 (22415)
2022 (26823)
2021 (27805)
2020 (23361)
2019 (16229)
2018 (11740)
2017 (13745)
2016 (11841)
2015 (14351)
2014 (10392)
2013 (7485)
2012 (7534)
2011 (7615)
2010 (7428)
Location
Africa (149)
Alabama (42)
Alaska (2)
Arizona (53)
Arkansas (5)
Asia (17318)
Australia (2936)
California (3883)
Canada (1144)
China (361)
Colorado (149)
Connecticut (152)
Delaware (103)
Europe (37256)
Florida (468)
Georgia (117)
Idaho (16)
Illinois (233)
India (10)
Indiana (92)
Iowa (2)
Japan (75)
Kansas (62)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (478)
Massachusetts (3096)
Michigan (70)
Minnesota (145)
Mississippi (1)
Missouri (24)
Montana (14)
Nebraska (4)
Nevada (17)
New Hampshire (14)
New Jersey (971)
New Mexico (12)
New York (1050)
North Carolina (556)
North Dakota (5)
Northern California (1714)
Ohio (112)
Oklahoma (9)
Oregon (21)
Pennsylvania (743)
Puerto Rico (6)
Rhode Island (19)
South America (209)
South Carolina (4)
Southern California (1496)
Tennessee (25)
Texas (450)
United States (13329)
Utah (53)
Virginia (79)
Washington D.C. (30)
Washington State (352)
Wisconsin (15)
268,201 Results for "rewind therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
CervoMed Inc., a clinical stage company focused on developing treatments for age-related neurologic disorders, announced that it has completed enrollment in RewinD-LB, a Phase 2b trial evaluating neflamapimod in patients with dementia with Lewy bodies.
June 11, 2024
·
5 min read
Press Releases
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
December 10, 2024
·
8 min read
Press Releases
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
October 15, 2024
·
6 min read
Drug Development
EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies
EIP Pharma Inc. today announced that the first patient has been dosed in the Company’s RewinD-LB Phase 2b clinical trial of neflamapimod for the treatment of patients with dementia with Lewy bodies (DLB).
August 14, 2023
·
12 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Layoffs
Spark Therapeutics Cuts 298 Employees as Part of Reorganization
Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of this year. Spark also trimmed its staff in 2024.
April 4, 2025
·
1 min read
·
Angela Gabriel
Press Releases
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
April 17, 2025
·
13 min read
Press Releases
Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics
April 15, 2025
·
7 min read
Press Releases
Nutcracker Therapeutics to Showcase NMU-Symphony™ Platform for Personalized Cancer Therapeutics at Leading Industry Conferences
May 1, 2025
·
3 min read
Press Releases
Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics
April 21, 2025
·
3 min read
1 of 26,821
Next
